Adoption of New Therapy for Autoimmune Diseases to Benefit Millions of Patients in Over 100 Countries
Professor Tadamitsu Kishimoto of the Osaka University, winner of the King Faisal International Prize for Medicine 2017, has stated that more than 100 countries, including Saudi Arabia, have adopted an effective biological approach in the treatment of autoimmune diseases, raising hopes for millions of people around the world who suffer from such diseases. The new treatment is significant considering that autoimmune diseases, which result from the failure of immune system cells to differentiate between the body’s tissues and cells, and alien tissues and cells, cause the body to fight against itself.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170708005001/en/
Professor Tadamitsu Kishimoto (Photo: ME NewsWire)
Professor Kishimoto, who was recently awarded the prestigious prize for the discovery of endogenous chemical interleukin-6’s (IL-6) pathway and its role in inflammatory and autoimmune diseases, said this while delivering a lecture organised by the King Faisal International Prize at the College of Medicine at the King Saud University in Riyadh. This lecture reflected the King Faisal International Prize’s efforts to promote the dissemination, transfer and localisation of knowledge by honouring humanitarian achievements and celebrating everything that serves people and improves their wellbeing.
A world-renowned immunologist, Professor Kishimoto has, through his research during the last 30 years, developed an IL-6 receptor-blocking antibody that has been recognized as the first approved treatment for diseases such progressive sclerosis and rheumatoid arthritis.
“The discovery of IL-6 receptor-blocking antibody has led to a major breakthrough in the treatment of autoimmune diseases. It has been approved for treatment in over 100 countries, including Saudi Arabia, Japan, the EU, and the US. Today almost one million people suffering from such diseases are being successfully treated with this antibody,” stated Kishimoto.
Besides being an immune protein, IL-6 is responsible for fever in autoimmune, infectious or non-infectious diseases, and is produced in the body wherever there is inflammation. IL-6 is implicated in a wide variety of inflammation-associated diseases, including diabetes mellitus and systemic juvenile rheumatoid arthritis.
The discovery of the antibody has not only led to the treatment of inflammatory diseases but has also paved the way for the training of several immunologists in all parts of the world, added Professor Kishimoto.
The King Faisal International Prize in Medicine has earlier been awarded to two researchers from Japan. Tetsuro Fujiwara was the first recipient when he shared the award with Bengt A. Robertson of Sweden in 1996 for research on the management of Neonatal Respiratory Distress Syndrome. Shinya Yamanaka was the second winner, sharing the prize in 2011 with James Alexander Thomson of USA. Yamanaka later won the Nobel Prize in 2012.
To know more about King Faisal International Prize, visit our website:
*Source: ME NewsWire
Om Business Wire
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Madison Realty Capital Provides $64.0 Million Construction Financing for 200 Kent Avenue Development in Williamsburg, Brooklyn17.11.2017 16:20 | Pressemelding
Madison Realty Capital (MRC) announced the closing of a $64.0 million construction loan for 200 Kent Avenue, a 117,326 square foot mixed-use development located in Williamsburg, Brooklyn. The retail portion of the property, which will include over 600 feet of frontage, will be anchored by a popular national grocery chain. Overall, the project will offer 50,101 square feet of retail space, 22,055 square feet of office and restaurant space, and 45,170 square feet of parking. “We continue to establish MRC as the one-stop shop for financing transitional real estate, including ground-up development deals like 200 Kent Avenue,” said Josh Zegen, Co-Founder and Managing Principal of MRC. “In this case, we’re working with a repeat MRC borrower who understands our ability to execute efficiently, given our firm’s up-to-the minute knowledge of local market conditions and non-bureaucratic approach to
Ncardia Announces Completion of €10.5M Investment Round17.11.2017 12:31 | Pressemelding
Ncardia, an emerging drug discovery and development stem cell technology company whose mission is to deliver cardiac and neural solutions based on its best-in-class human induced pluripotent stem cell (iPSC)-derived technology, today announced the completion of a €10.5 million series B financing round. The round was led by Épimède, a Belgium venture capital firm. Ncardia is a privately-held company with operations in Europe and the US, that produces and commercializes high-quality, fully-functional human iPSC-derived cardiovascular and neuronal cell types. Using its cell products, Ncardia develops and commercializes assay services for drug safety and efficacy testing. Additionally the company has built up a strong portfolio of patents covering the use of stem cell models for these applications. Stefan Braam, CEO of Ncardia, commented: “At Ncardia, important progress h
Double Win for Vocalink at the 2017 Payments Awards17.11.2017 09:35 | Pressemelding
Vocalink, a Mastercard company, was last night awarded with two prestigious awards - The Overall Winner and the Payments Infrastructure of the Year Award, for its leading technology and expertise, and in recognition for a milestone year that saw Vocalink’s solutions transform the way people and businesses move money across the globe. 2017 saw Vocalink deliver ground-breaking immediate payments solutions both in the US and Thailand as well as enabling access to the UK payments industry through their payments gateway solution PayPort. The business also saw the launch of the new image based cheque clearing system, creating a robust and more efficient system in the UK. RTP ® in the US: This week, Vocalink announced the launch of RTP® (Real-Time Payments) in the US on behalf of The Clearing House; one of the most comprehensive real-tim
Envion AG: Start-up from the Heart of Berlin Has Pioneered Decentralized Mobile Mining by Combining Blockchain with Regenerative Energy17.11.2017 09:00 | Pressemelding
Envion AG has created a technology for the first truly mobile data-center that uses low-priced local energy to mine a broad spectrum of cryptocurrencies (Bitcoin, Ethereum, etc.). By harvesting locally available clean energy right at the source, envion can operate at lower costs than competitors and at the same time reduces the CO2 footprint of the blockchain industry. Envion aims at decentralizing the highly-concentrated mining market (China holds 80% in Bitcoin mining) and at bringing control of the market back to the users. That’s why envion gives 100% of its mining profits back to its community. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171117005011/en/ Envion - World's Most Profitable Standard of Self-Expanding Crypto Infrastructure (Photo: Business Wire) Current challenges in the energy
Chugai's HEMLIBRA® Receives the World's First Regulatory Approval from FDA for Hemophilia A with Inhibitors16.11.2017 23:30 | Pressemelding
Chugai Pharmaceutical Co., Ltd. (TOKYO:4519) announced today that the U.S. Food and Drug Administration (FDA) has approved the bispecific antibody emicizumab (US product name: HEMLIBRA®) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients with hemophilia A (congenital factor VIII deficiency) with factor VIII inhibitors. This represents the first regulatory approval for HEMLIBRA® around the world. The US Biologics License Application (BLA) was submitted by Genentech, a member of Roche Group. “We are pleased that HEMLIBRA, a biopharmaceutical created by Chugai scientists based on their exceptional idea, has received its first regulatory approval,” said Chugai’s President & COO, Tatsuro Kosaka. “HEMLIBRA is a first in class biopharmaceutical which is an advancement on the current limited treatment options available for pat
Pacific Drilling Receives Approval of First Day Motions16.11.2017 22:08 | Pressemelding
Pacific Drilling S.A. (OTCPink: PACDQ) (“Pacific Drilling” or the “Company”) today announced that the United States Bankruptcy Court for the Southern District of New York has granted the relief requested by the Company in certain first day motions related to ordinary course business activities, subject to certain modifications at the request of the Court, the United States Trustee and stakeholders. The approved motions give us the authority to, among other things, continue to pay employee wages and benefits without interruption, to utilize our current cash management system, and to pay certain foreign and critical vendors for goods and services provided prior to the petition date. All vendors will be paid in full and in cash on normal payment terms for all goods and services provided on or after the petition date. Paul Reese, Chief Executive Officer of Pacific Drilling, said, “With the
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom